October 7, 2023

Gal­der­ma’s an­nu­al push, and fund­ing do­na­tion, for breast can­cer aware­ness dur­ing Oc­to­ber this year is fo­cused on the per­son­al sto­ries of sur­vivors who’ve used its

Cov­er­ing an­ti-obe­si­ty med­ica­tions through Medicare would sig­nif­i­cant­ly in­crease fed­er­al spend­ing, the Con­gres­sion­al Bud­get Of­fice said in an analy­sis pub­lished Thurs­day con­clud­ing that more re­search is

Oral drugs have raced to the front of the pack in the crowd­ed mi­graine ther­a­py space and ap­pear to be stay­ing put with physi­cians. Pri­ma­ry

Pop­u­lar weight loss drugs are like­ly be­ing dis­count­ed by half or more from their list prices, ac­cord­ing to a new study, a gap that’s ex­pect­ed

Pro­mo­some, Pfiz­er and BioN­Tech told a Cal­i­for­nia fed­er­al judge that they have agreed to re­solve Pro­mo­some’s law­suit ac­cus­ing the two com­pa­nies of vi­o­lat­ing a patent

More than a year af­ter it was ap­proved for adults and chil­dren 12 years and old­er, Ar­cutis Bio­ther­a­peu­tics’ steroid-free top­i­cal cream for plaque pso­ri­a­sis is

It was 4:45 a.m. on May 27. Cat Jamieson, a promi­nent can­cer stem cell re­searcher, was at her home in San Diego wrap­ping up a

Re­gen­eron pays out $100M proof-of-prin­ci­ple mile­stone: Re­gen­eron said Thurs­day it will take a $100 mil­lion charge in the third quar­ter af­ter pay­ing out a de­vel­op­ment

Mi­rati Ther­a­peu­tics is once again at­tract­ing buy­out in­ter­est, this time al­leged­ly from Sanofi, ac­cord­ing to a re­port from Bloomberg on Thurs­day. The biotech’s shares $MRTX surged by